Delivery of therapeutic agents through intracerebroventricular (ICV) and intravenous (IV) injection in mice - PubMed (original) (raw)
Delivery of therapeutic agents through intracerebroventricular (ICV) and intravenous (IV) injection in mice
Jacqueline J Glascock et al. J Vis Exp. 2011.
Abstract
Despite the protective role that blood brain barrier plays in shielding the brain, it limits the access to the central nervous system (CNS) which most often results in failure of potential therapeutics designed for neurodegenerative disorders. Neurodegenerative diseases such as Spinal Muscular Atrophy (SMA), in which the lower motor neurons are affected, can benefit greatly from introducing the therapeutic agents into the CNS. The purpose of this video is to demonstrate two different injection paradigms to deliver therapeutic materials into neonatal mice soon after birth. One of these methods is injecting directly into cerebral lateral ventricles (Intracerebroventricular) which results in delivery of materials into the CNS through the cerebrospinal fluid. The second method is a temporal vein injection (intravenous) that can introduce different therapeutics into the circulatory system, leading to systemic delivery including the CNS. Widespread transduction of the CNS is achievable if an appropriate viral vector and viral serotype is utilized. Visualization and utilization of the temporal vein for injection is feasible up to postnatal day 6. However, if the delivered material is intended to reach the CNS, these injections should take place while the blood brain barrier is more permeable due to its immature status, preferably prior to postnatal day 2. The fully developed blood brain barrier greatly limits the effectiveness of intravenous delivery. Both delivery systems are simple and effective once the surgical aptitude is achieved. They do not require any extensive surgical devices and can be performed by a single person. However, these techniques are not without challenges. The small size of postnatal day 2 pups and the subsequent small target areas can make the injections difficult to perform and initially challenging to replicate.
Figures
References
- Blanchette M, Fortin D. Blood-brain barrier disruption in the treatment of brain tumors. Methods Mol. Biol. 2011;686:447–463. - PubMed
- Snyder EY, Taylor RM, Wolfe JH. Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain. Nature. 1995;374:367–370. - PubMed
- Kienstra KA, Freysdottir D, Gonzales NM, Hirschi KK. Murine neonatal intravascular injections: modeling newborn disease. J. Am. Assoc. Lab. Anim. Sci. 2007;46:50–54. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 HD054413/HD/NICHD NIH HHS/United States
- R01 NS041584/NS/NINDS NIH HHS/United States
- R01NS41584/NS/NINDS NIH HHS/United States
- R01HD054413/HD/NICHD NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical